Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.
Circulating tumor DNA (ctDNA) is a promising tool for diagnosing and predicting cancer prognosis. However, its clinical utility in metastatic renal cell carcinoma (mRCC) remains unclear, particularly in terms of clinical prognosis. We enrolled 124 patients with mRCC in the MONSTAR-SCREEN study ...
Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.
Background: Patients with chronic kidney disease (CKD) or post-kidney transplant have an elevated risk of renal cell carcinoma (RCC).
... renal cell carcinoma. Provisionally accepted. Cheng Chen1 Yanfeng Shen1 Yanhong Ma2 Yingying Zhang ...
Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.
A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.
Chimeric antigen receptor (CAR) macrophage therapy has shown promising activity in preclinical models of solid tumors. A platform that combines CAR technology with lipid nanoparticles for in vivo macrophage engineering is now shown to generate pro-inflammatory CAR macrophages with sustained ...
A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.
Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.